One Prescription Does Not Fit All: How Your Unique Biology May Be Working Against Your Treatment

When a physician writes a prescription, the decision is rarely arbitrary. It is grounded in clinical training, evidence-based guidelines, and years of accumulated research. Yet for millions of Americans, the medication they walk out of the pharmacy with may be delivering suboptimal results — not because their doctor made an error, but because the science behind that prescription was never built with them specifically in mind.

This is not a criticism of modern medicine. It is, rather, an honest examination of how the healthcare system has historically approached drug therapy: through population averages rather than individual biology.

How Clinical Guidelines Are Built — and Where They Fall Short

Clinical practice guidelines are developed by professional medical organizations using data aggregated from large patient populations. When the American Heart Association recommends a particular class of antihypertensive medication, or when guidelines suggest a specific antidepressant as a first-line treatment, those recommendations reflect outcomes measured across thousands — sometimes hundreds of thousands — of study participants.

The problem is that averages, by definition, do not describe any single person with precision. A drug that demonstrates a statistically significant benefit across a trial population may still underperform — or cause harm — in a meaningful subset of individuals who metabolize it differently, carry certain genetic variants, or manage multiple coexisting health conditions simultaneously.

For the patient sitting across from their physician, this statistical reality rarely surfaces in conversation. The prescription gets written. The medication gets filled. And if results are disappointing, the assumption is often that the drug needs to be adjusted in dose or switched to an alternative — a trial-and-error process that can stretch across months or years.

The Role of Pharmacogenomics in Changing the Equation

Pharmacogenomics — the study of how a person's genetic makeup influences their response to drugs — represents one of the most significant shifts in pharmaceutical science in recent decades. Specific genes govern the activity of enzymes responsible for metabolizing medications in the body. Variations in these genes can mean the difference between a drug working effectively, failing to produce any therapeutic benefit, or accumulating to dangerous levels in the bloodstream.

Consider a commonly prescribed antidepressant processed by the liver enzyme CYP2D6. Patients who carry genetic variants that cause them to metabolize the drug too rapidly may never achieve adequate blood concentrations, leaving them with little relief from their symptoms. Conversely, those classified as poor metabolizers may experience intensified side effects from doses that would be entirely routine for another patient.

Similar dynamics play out across a wide range of drug classes, including blood thinners, pain medications, antipsychotics, and certain chemotherapy agents. The FDA has already incorporated pharmacogenomic information into the labeling of more than 200 approved medications — an acknowledgment that genetic factors are not peripheral considerations but central ones.

Despite this, pharmacogenomic testing remains underutilized in routine clinical care across the United States. Cost, limited provider familiarity, and inconsistent insurance coverage have all contributed to its slow adoption outside of specialized oncology or psychiatry settings.

Comorbidities: When One Condition Complicates Another

Genetics is only one dimension of the mismatch between standard prescribing and individual need. Comorbidities — the presence of two or more chronic conditions in a single patient — introduce a layer of complexity that clinical guidelines often fail to fully address.

Guidelines for managing Type 2 diabetes, for example, are developed with the diabetic patient as the primary subject. But the majority of adults with diabetes in the United States also carry diagnoses of hypertension, dyslipidemia, or chronic kidney disease. When multiple conditions are present, the medications appropriate for each condition may interact with one another, compete for the same metabolic pathways, or exacerbate a symptom that a different drug is simultaneously trying to control.

This is not a rare scenario. It is the daily reality for a substantial portion of American patients, particularly those over the age of 60. Yet many clinical guidelines are still developed in silos, addressing one condition at a time without fully accounting for the pharmaceutical burden that accompanies complex, multi-system disease.

Precision Medicine: Progress and Practical Limitations

The promise of precision medicine — tailoring treatment to the individual rather than the population — has generated considerable momentum in both research and policy circles. Initiatives such as the National Institutes of Health's All of Us Research Program reflect a growing institutional commitment to building datasets diverse enough to inform truly individualized care.

In practice, however, precision medicine remains more aspirational than accessible for most patients. Genetic testing is not yet a standard component of primary care visits. Algorithms capable of integrating a patient's full clinical profile — genetics, comorbidities, current medications, lifestyle factors — into a single prescribing recommendation do not yet exist in a form that is widely deployable at the point of care.

What does exist, increasingly, is a body of knowledge that both physicians and patients can begin to draw upon — if they know to ask for it.

Questions Every Patient Should Bring to Their Next Appointment

The gap between what is prescribed and what is optimal is not always inevitable. Patients who engage actively in their own care are better positioned to surface information that may not otherwise enter the clinical conversation. Consider raising the following with your prescriber or pharmacist:

• Has pharmacogenomic testing been considered for this medication? For certain drug classes — particularly psychiatric medications, blood thinners, and some pain management therapies — genetic testing may already be clinically supported and potentially covered by insurance.

• Does this prescription account for all of my current conditions and medications? Physicians managing a specific condition may not have immediate visibility into the full scope of a patient's pharmaceutical regimen. Bringing a complete, updated medication list to every appointment is essential.

• What is the monitoring plan if this medication does not perform as expected? Understanding the benchmarks for success — and the timeline for reassessment — helps patients avoid prolonged exposure to a treatment that may not be appropriate for them.

• Are there alternatives that have been studied in patients with my specific profile? Research populations are not always representative. Some medications have stronger evidence bases for certain demographic groups, age ranges, or comorbidity combinations than others.

The Patient's Role in Closing the Gap

The shift toward more individualized prescribing will not happen overnight. It requires investment in infrastructure, training, and data systems that are still being built. But patients do not need to wait passively for those systems to mature.

Armed with the right questions and a clear understanding of how population-based prescribing works — and where it has limits — patients can advocate more effectively for treatment decisions that reflect who they are, not just who the average trial participant happened to be.

Your prescription is a starting point. Whether it becomes the right answer depends, in no small part, on the conversation you are willing to have.